A Combination of Savolitinib and Osimertinib Prolongs PFS in Patients with EGFR-mutated NSCLC and Acquired MET Amplification After Progression On a First-Line EGFR TKI By Ogkologos - January 16, 2026 1 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SACHI study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Conditional Marketing Authorisation for Nogapendekin alfa Inbakicept Patient Guide in Testicular Cancer Now Available Also in German AI Model Identifies How Every Country Can Improve Its Cancer Outcomes MOST POPULAR ESMO Breast Cancer 2025, Munich, Germany, 14-17 May 2025 May 7, 2025 Exploring Coping Resources to Help with Physical, Practical, and Emotional Challenges... January 8, 2024 Mutation Screening Could Reveal Whether Hormone Treatment Will Work for Breast... April 23, 2021 First Direct Comparison of Ibrutinib versus Acalabrutinib in Patients with Previously... August 3, 2021 Load more HOT NEWS Virtual Mind–Body Fitness Classes Show Unexpected Benefit in People with Cancer Significantly Longer PFS with First-line Pembrolizumab for MSI-H/dMMR mCRC Qué saber sobre los diferentes tipos de mastectomías para el cáncer... Political Interests Are A Major Adversary in the War on Women
